Shares of Vivos Therapeutics (NASDAQ:VVOS) climbed on Wednesday after MedTech announced the FDA's 510(k) clearance for its DNA appliance as a treatment for children with obstructive sleep apnea ...
Vivos Therapeutics shares rose on Wednesday after the company said its oral medical device for pediatric sleep apnea and snoring received 510(k) clearance from the Food and Drug Administration.
Vivos believes this breakthrough regulatory clearance represents a huge opportunity to capture significant market share. Recent published studies report up to 10.1 million U.S. children (ages 6-17 ...
Results that may be inaccessible to you are currently showing.